Magnesium oxide (DrugBank: Magnesium oxide, Magnesium)
3 diseases| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 2 |
| 166 | Pseudoxanthoma elasticum | 1 |
| 291 | Hirschsprung disease, entire colon type | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000022023 | 2016/05/10 | 10/05/2016 | A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease. -to evaluation by change of intestinal bacterial flora- | Parkinson diseaseChronic constipation | Study drug group: A 12-week administration of lubiprostone 24 microgrum (adjustable) twice daily after switching from magnesium oxide Control group: Continuous administration of magnesium oxide at the same dosage regimen as before the enrollmen | Dokkyo Medical University | NULL | Complete: follow-up complete | 20years-old | 90years-old | Male and Female | 64 | Not selected | Japan | |
| 2 | JPRN-UMIN000022022 | 2016/05/10 | 10/05/2016 | A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease | A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease - A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease | Parkinson diseaseChronic constipation | Study drug group: A 12-week administration of lubiprostone 24 microrgrum (adjustable) twice daily after switching from magnesium oxide Control group: Continuous administration of magnesium oxide at the same dosage regimen as before the enrollment | Dokkyo Medical University | NULL | Complete: follow-up complete | 20years-old | 90years-old | Male and Female | 64 | Not selected | Japan |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01525875 (ClinicalTrials.gov) | August 2012 | 1/2/2012 | Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE) | Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE) | Pseudoxanthoma Elasticum | Drug: Magnesium Oxide;Drug: Placebo | Mark Lebwohl | NULL | Completed | 18 Years | N/A | All | 44 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03593252 (ClinicalTrials.gov) | September 1, 2018 | 22/5/2018 | Bowel Preparation in Elective Pediatric Intestinal Surgery | Mechanical Bowel Prep and Prophylactic Oral Antibiotic Use in Children: Implications for Intestinal Surgery Complications | Colostomy Stoma;Ileostomy - Stoma;Jejunostomy Stoma;Hirschprung's Disease;NEC;Inflammatory Bowel Diseases;Meconium Ileus;Bowel Obstruction | Drug: Senna;Drug: Sodium Picosulfate, Magnesium Oxide and Citric Acid;Drug: Erythromycin;Drug: Kanamycin;Drug: Cefazolin;Drug: Metronidazole;Other: Nil per os | McMaster University | NULL | Not yet recruiting | 6 Months | 18 Years | All | 48 | N/A | NULL |